52-Week Highs and Lows, Thursday May 7, 2026

13 new 52-week highs, 7 new 52-week lows, 20 total alerts on the Thursday close.

Highs

VXUS .. $85.67 .. Vanguard Total International Stock ETF. Broad international tape pushing fresh highs as the dollar softens and Europe and EM bid follow through. Closed at $84.25 after fading from the intraday print.

QQQM .. $288.70 .. Invesco NASDAQ 100 ETF. Mega-cap tech leadership intact. Closed at $286.12, basically flat on the day.

VTI .. $362.27 .. Vanguard Total Stock Market ETF. The full US market tape at fresh highs alongside QQQM. Goldilocks setup for now.

CLYM .. $12.48 .. Climb Bio. Miami Tier 1 autoimmune CAR-T name continuing to ride the cell therapy bid. Closed at $11.91, faded a bit but still on the highs.

TGTX .. $42.09 .. TG Therapeutics. Briumvi MS franchise driving the move. Stock actually printed an intraday $44 and closed $43.03, so the 52w break has real follow-through.

FATE .. $2.46 .. Fate Therapeutics. Off-the-shelf iPSC CAR-NK platform getting bid as cell therapy heat spreads. Closed up 6.1% at $2.43. Long descent from the $50s but the chart is finally curling.

LION .. $13.00 .. Lionsgate Studios Corp. Pure-play content M&A setup. Netflix acquisition chatter the obvious driver. Closed at $12.38, faded 3% from the high but the breakout is on the tape. M&A Watch.

ASTH .. $36.20 .. Astrana Health. Healthcare services name quietly making new highs while the rest of the sector chops. Closed at $36.08.

TSHA .. $7.30 .. Taysha Gene Therapies. Rett syndrome gene therapy name. Heads up, the alert print of $7.30 does not match my data feed which shows an intraday max of $7.025 and a close of $6.67. Want me to verify before this one ships in the final.

OCS .. $31.33 .. Oculis Holding AG. Miami Tier 3, Swiss ophthalmic. OCS-01 DIAMOND Phase 3 DME readout on track for June 2026, Licaminlimab anti-TNFα PREDICT-1 also active. Closed up 5.1% at $31.09. Sneaky setup into the catalyst window.

LNTH .. $93.00 .. Lantheus Holdings. Radiopharm leadership. Closed up 5.6% at $91. The space heat is real, every radiopharm name catching a bid.

CARE .. $26.58 .. Carter Bankshares. Regional bank quietly pushing highs while the group is sleepy. Closed at $26.19.

AVTX .. $24.27 .. Avalo Therapeutics. Miami Tier 3, AVTX-009 anti-IL-1β for hidradenitis suppurativa. Closed up 4.9% at $22.87, faded hard from the high but the trend is intact.

Lows

NAGE .. $4.04 .. Niagen Bioscience. Q1 print Tuesday after close, FY guide for higher S&M and G&A spend triggered a margin compression sell-off. Closed at $4.19, down 15.7% on the day. Telehealth Niagen Plus pivot is still the story but the tape is unforgiving.

ARTL .. $2.64 .. Artelo Biosciences. FABP5 inhibitor name. Down from $85.80 a year ago to $2.64. Microcap meltdown continuing despite recent peer-reviewed publication. Closed at $2.68.

BBOT .. $7.60 .. BridgeBio Oncology Therapeutics. Miami Tier 3, KRAS-focused oncology. Closed at $7.86, bounced into the close. Weak hands shaken on the print, watch for a base here.

PTNT .. $25.49 .. Corgi IP Licensing and Royalties ETF. Low-volume newer ETF, basically flat on the session. Not Palatin Technologies, that ticker moved to PTN after the Nov 2025 uplisting.

AKBA .. $1.13 .. Akebia Therapeutics. Miami Tier 3, vadadustat for anemia in CKD. Closed at $1.18, down 20.3% on the day. Need to dig into the catalyst, no clean print explains the move yet. Flagging for follow-up.

INBS .. $2.27 .. Intelligent Bio Solutions. Microcap diagnostics name continuing the slide. Closed at $2.29.

KBR .. $33.04 .. KBR Inc. Government services contractor under pressure on broader Pentagon budget chatter. Closed at $33.20, down 5.4% on the day.

Summary

Broad tape strong with VXUS, QQQM, VTI all at fresh highs, but underneath the surface biotech and radiopharm are doing the heavy lifting. CLYM, TGTX, FATE, OCS, LNTH, TSHA, AVTX all new 52w highs in a single session is a real signal that the cell therapy and ophthalmic bid is broadening. Lionsgate added the M&A flavor on the day. The ugly side belongs to AKBA -20% with no clean print I can find, NAGE -15.7% post the Q1 guide, and the slow ARTL bleed from $85.80 to $2.64 over twelve months. Two flags before this ships, the TSHA $7.30 alert does not match my verification data, and AKBA needs a catalyst dig.